Melphalan - Study guides, Class notes & Summaries

BMTCN-- Question and answers already passed 2023/2024 What type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

BMTCN2 Question and answers correctly solved 2023/2024 What type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers -...

BMTCN ch.04preparative regimens - correct answer aka conditioning regiment part of HSCT when tx malignant diseases goal: eradicate residual disease and/or provide immunosuppression to prevent graft rejection prepare receipients bone marrow to accept new donor cells examples of chemo - correct answer cyclophosphamide busulfan etoposide cytarabine carmustine melphalan myeloablative regimens - correct answer lethal doses of chemo (usually includes alkylating agents) with or without TB...

3.2.2. New agents Immunomodulatory drugs (IMIDs) and proteasome inhibitors (PIs), now widely used in antimyeloma therapy, have significantly improved survival of MM patients [33,34]. There is an increasing evidence in the literature that these agents may also improve the outcome in pPCL, but the benefit is less apparent when compared with MM. Bortezomib is probably the key new agent in pPCL, and, when used in drug combination, rapidly reduces tumor load and reverses complications s...

ONS fundamentals Exam Questions and Answers 100% Pass when chemo is used before primary treatment (surgery) to reduce the size of a tumor - Correct Answer ️️ -neoadjuvant therapy neoadjuvant therapy is common for what 2 kind of cancers? - Correct Answer ️️ -colon and breast when chemo is used after primary (surgery, radiation) - Correct Answer ️️ -adjuvant induction - Correct Answer ️️ -start of chemo consolidation - Correct Answer ️️ -testing labs and such after chem...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

BMTCN TEST B ACTUAL QUESTIONS AND ANSWERS 2024 GRADED A+ Transplant-related toxicity is a barrier that contributes to the under utilization for which of the following diseases? A. Non-Hodgkin lymphoma B. Acute myeloid leukemia C. Sickle cell disease D. Neuroblastoma Ans- C. Sickle cell disease Despite success of HSCT in sickle cell disease, barriers to successful HSCT include lack of a suitable donor, transplant related toxicity and immunologic graft rejection. Which of the foll...

Immunoglobulins are secreted by which type of cell? A. B-lymphocyte B. Megakaryocyte C. T-lymphocyte D. Natural killer A. B-lymphocyte B lymphocytes synthesize and secrete immunoglobulins. Which portion of the immunoglobulin activates the complement pathway? A. MHC Class I B. Fab C. Fc D. MHC Class II C. Fc The Fc region activates the complement pathway. Which of the following is a class II HLA antigen? A. B B. DR C. A D. C B. DR HLA DR, DQ and DP are ...

BMTCN ch.04 preparative regimens - correct answer aka conditioning regiment part of HSCT when tx malignant diseases goal: eradicate residual disease and/or provide immunosuppression to prevent graft rejection prepare receipients bone marrow to accept new donor cells examples of chemo - correct answer cyclophosphamide busulfan etoposide cytarabine carmustine melphalan myeloablative regimens - correct answer lethal doses of chemo (usually includes alkylating agents) with or without ...